This study aims to evaluate feasibility of a virtual reality software device and measure the effects of the intervention on OUD patient mood, tension and cravings, as well as the effect of treatment on patient retention to their inpatient detox protocol.
The primary objective of this study is to evaluate the feasibility and preliminary effectiveness of a novel virtual reality (VR) based intervention; 3D Therapy Thrive (3DTT). Inpatient detoxification can improve outcomes for individuals with opioid use disorder (OUD), however patients often leave treatment early due to mood, tension, and cravings associated with opioid withdrawal. Subjects were recruited from a community inpatient detoxification program and received up to two sessions of 3DTT. The patients completed surveys to assess their mood, distress, cravings, and overall satisfaction with the experience. Retention was measured by protocol completion as reported by clinic staff, independent of the study. A group of patients with OUD consecutively admitted to the program comprised a comparison treatment-as-usual (TAU) group.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DEVICE_FEASIBILITY
Masking
SINGLE
Enrollment
40
A novel virtual reality software intervention that utilizes elements of Cognitive Behavioral Therapy to improve outcomes for inpatients with OUD.
The Gavin Foundation
Quincy, Massachusetts, United States
Retention in Treatment
Medical record indicating whether patient completed detox protocol (i.e., completed, left against medical advice, administratively discharged, or moved to higher level of care)
Time frame: At departure from facility, through study completion, an average of 10 days
Feasibility and Tolerability of 3DTT
Feasibility and tolerability of 3DTT was measured by the Side Effects Questionnaire.
Time frame: Immediately after each treatment
Mood
Depressive symptoms as measured by the AB-POMS depression scale (0-4, not at all to extremely)
Time frame: Before and after each treatment, approximately every other day for up to 5 days
Anxiety
Anxiety symptoms as measured by the AB-POMS scale (0-4, not at all to extremely)
Time frame: Before and after each treatment, approximately every other day for up to 5 days
Cravings
Opioid cravings as measured by the Visual Analog Scale (1-10, with higher scores indicating greater cravings.)
Time frame: Before and after each treatment, approximately every other day for up to 5 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.